Scale bars, 50 m (control tissues and bottom images of liver) or 250 m (top images of liver)
But FDA approval for uses other than diabetes and obesity will likely take several more years, after large clinical trials are completed
At the centre of this innovation is SAIFx technology, the proprietary approach that powers every GMPriority Pharma and lipolife product
Onceweekly dulaglutide versus oncedaily liraglutide in metformintreated patients with type 2 diabetes (AWARD6): a randomised, openlabel, phase 3, noninferiority trial
Reversible lipidization for the oral delivery of salmon calcitonin
Understanding your genetic responder profile before surgery helps your PlexusDx provider optimize your post-operative restart dose, potentially improving tolerability and faster return to your therapeutic goals